Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
No trials found
News
Marksans Pharma Secures UK MHRA Approval for Exemestane Breast Cancer Treatment
Marksans Pharma's UK subsidiary Relonchem received marketing authorization from UK MHRA for Exemestane 25mg film-coated tablets, a breast cancer treatment.
Marksans Pharma Subsidiary Receives FDA Establishment Inspection Report Following New York Facility Review
Time-Cap Laboratories, a subsidiary of Marksans Pharma, received an establishment inspection report from the US FDA following a cGMP inspection at its New York facility conducted in April 2025.
Marksans Pharma Subsidiary Receives UK Marketing Authorization for Metformin Oral Solution
Marksans Pharma's subsidiary Relonchem Ltd received UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) marketing authorization for Metformin Hydrochloride oral solution in 500 mg/5 ml strength.